Recently, our company’s controlled subsidiary, Beijing Huonland Pharmaceutical Co., Ltd. (hereinafter referred to as “Huonland”), has obtained the “Drug Registration Certificate” for “Moxifloxacin Hydrochloride Eye Drops,” approved and issued by the National Medical Products Administration. The drug approval number is: National Drug Approval No. H20223332, and the registration classification is Category 4 chemical drug. With this approval, Huonland now has four ophthalmic drug products on the market, including three multi-dose eye drops (Bromothymol Blue Eye Drops, Olopatadine Hydrochloride Eye Drops, and Moxifloxacin Hydrochloride Eye Drops) and one single-dose eye drop (0.3% Sodium Hyaluronate Eye Drops).

        The moxifloxacin hydrochloride eye drops recently approved are indicated for the treatment of bacterial conjunctivitis. Bacterial conjunctivitis is an inflammatory disease caused by bacterial or other pathogenic microbial infections of the ocular tissues. Patients typically experience conjunctival hyperemia and redness, accompanied by symptoms such as pain, itching, and increased ocular discharge. In some patients with more severe infections, visual impairment or other vision disturbances may also occur. Currently, there are numerous products available on the market for treating bacterial conjunctivitis. Moxifloxacin hydrochloride is a fourth-generation quinolone drug—a compound belonging to the "8-methoxyfluoroquinolone" class. Compared to third-generation quinolones, it boasts a broader antibacterial spectrum and better resistance profile. Moreover, it does not exhibit cross-resistance with other antibiotic classes, giving it distinct advantages in clinical use.

        Huonland is professionally dedicated to the manufacturing and distribution of ophthalmic pharmaceutical products. The company boasts advanced eye-drop production lines and a comprehensive GMP management system. Having entered a phase of robust business performance, Huonland has achieved rapid growth in its financial results through diversified business models, including proprietary drug distribution, CDMO services under the MAH system, and collaborative development of new products. In 2021, Huonland’s sales revenue from eye-drop products reached 46.76 million yuan, an increase of 34.88 million yuan over the previous year, representing a 293% growth in pharmaceutical sales revenue. In the first quarter of 2022, the company’s sales revenue from eye drops amounted to 14.71 million yuan, up 86.5% compared to the same period last year.

        The approval of moxifloxacin hydrochloride for market launch is expected to further enhance the company’s overall business performance. In addition to the four eye-drop products already approved and on the market, the company currently has other products in development. Balanced salt solution, 0.1% sodium hyaluronate single-dose and multi-dose eye drops, dexamethasone sodium phosphate eye drops, brimonidine tartrate eye drops 5 items The variety is under review. We are currently developing more than 10 product candidates, covering a variety of therapeutic areas including dry eye syndrome, conjunctivitis, glaucoma, and antimicrobial treatments. The company will accelerate R&D efforts, actively organize production, and continue to provide high-quality ophthalmic pharmaceutical products to the market. At the same time, we will keep offering industry clients integrated solutions for the R&D and manufacturing of eye drops, as well as end-to-end services across the entire value chain. As our portfolio of ophthalmic products continues to expand, revenue from ophthalmic pharmaceuticals will become a new growth driver for the company, playing a positive role in supporting the R&D and commercialization of innovative biopharmaceuticals.